SBIR/STTR Research Award

Biointegrated Synthetic Grafts for Reconstruction of Vascular Tissues

Award identifier 95d5cfd01542a5021d6b7a28f0bb18a51c66e8c3d32a1022cd7b20bd171fb764Awarding agency Department of Defense · Defense Health Agency

Award amount

$149,978

Program and phase

SBIR · Phase I

Award year

2014

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Defense
Branch
Defense Health Agency
Recipient company
HEALIONICS CORPORATION
Proposal award date
2014-11-06
Contract end date
2015-06-09
UEI
KS25PLAKN3X3
Solicitation number
2014.1
Topic code
DHP14-009

Research abstract

Current vascular repair and replacement grafts made from synthetic biomaterials, typically expanded polytetrafluoroethylene (ePTFE), have poor functionality for use with smaller vessels in the extremities. We propose using ?STAR? synthetic biomaterial, a well developed microporous tissue scaffold, already in human device use, to construct grafts that potentially overcome the issues with stenosis and infection that limit use of existing prosthetic graft materials. When implanted, STAR biomaterial exhibits large reductions in foreign body response, enhances angiogenesis, and concentrates natural immune cells to resist infections. These biological responses are regulated by the tightly controlled and optimized porous geometry, and do not require use of added biologics. By significantly reducing foreign body encapsulation around the graft exterior, ?STARgraft? reduces capsular contraction, a significant contributor to lumen narrowing. Use of STAR biomaterial on the inner blood-contacting surfaces offers potential to use the pore structure?s inherent proangiogenicity to facilitate capillary ingrowth and support spontaneous endothelialization. Since the biological responses to STAR biomaterial are largely independent of material chemistry, STARgraft can be constructed from well-characterized high-compliance elastomeric silicones highly suited for vascular graft use. Preliminary in vivo feasibility data in an arteriovenous shunt model suggests the approach has promise for the vascular reconstruction application.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

13 SBIR/STTR records share this UEI (2009–2024). Reported award amounts total $10,508,946. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Defense

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.